根据名称进行药物检索

Tapentadol 与 Zyvox

Tapentadol 与 Zyvox互相作用以及同时服用的可能性。

检测结果:

Tapentadol <> Zyvox

现实性: 12.08.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

如果你目前正在处理与他多，让你的医生之前知道你会收到利奈唑. 结合这些药物可以增加风险的一个罕见的，但严重的疾病叫做血清素综合症，其中可能包括的症状，如混乱、幻觉、扣押、极端变化血压，心率增加、发烧、多汗、颤抖或颤抖、视力模糊，肌肉痉挛或僵硬、震颤、不协调、胃痉挛、恶心、呕吐、腹泻。严重的情况下可能导致昏迷甚至死亡。根据你的情况，你的医生可以要你停止他多在你开始处理与利奈唑，或规定一种替代药物治疗。否则，你将需要密切监测通过你的医生在治疗。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

禁忌:共同给予的利奈唑有素的药剂可以使可能的风险的血清素综合症，这是一个罕见的，但是严重的和潜在的致命状况的思想导致过度刺激的脑干5-HT1A和2A受体。利奈唑是可逆的、非选择性的单胺氧化酶抑制剂(单胺氧化酶抑制剂). 为此，它可以提高素效果可以通过抑制血清素的新陈代谢。罕见的情况下的血清素综合症已经报告了协会与利奈唑使用，最常见的结合血清素再吸收抑制剂。症状的血清素综合征可以包括精神状态的变化，例如烦躁、改变的意识，混淆，幻觉和昏迷;自主神经功能障碍如性心动过速、热疗、发汗解表、颤抖、血压不稳定，并散瞳;神经肌肉异常比如反射亢进、肌阵挛、震颤、刚性，并共济失调；和胃肠道症状，例如腹部绞痛、恶心、呕吐、腹泻。

管理：伴随使用的利奈唑和血清素的药剂应当避免，除非没有替代品的存在和密切监测对发展的血清素综合症可以提供。在一般情况下，最素精神药物应该停止1至2个星期(即，4至5个半衰期)之前治疗单胺氧化酶抑制剂，而其他人，例如氟西汀可能需要中止的5周前，由于其长时间的一半，生活。处理有素的药物可以继续24小时之后，最后一次剂量的利奈唑. 在紧急情况下，可能需要紧急治疗与利奈唑(例如，耐万古霉素球菌(净蛋白)感染；医院肺炎和复杂性皮肤及皮肤结构感染，包括情况下造成甲氧耐金黄色葡萄球菌)，提供替代的干预措施应被视为和利益利奈唑治疗应当是衡量风险的血清素的毒性。如果决定是由管理利奈唑患者接受一种血清素药物，血清素药物，必须立即停止，并且患者密切监测对紧急症状的中枢神经系统中毒两周(五个星期，如果氟西汀的是采取三个星期，如果vortioxetine被采取)或直到24小时之后，最后一次剂量的利奈唑，以先到者为准。病人和/或他们的护理人员应被告知寻求医疗照顾，如果潜在的症状的血清素综合症的发展。

来源

Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20
"Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3
Jones SL, Athan E, O'Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62
Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11
Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7
Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197
Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4
Clark DB, Andrus MR, Byrd DC "Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature." Pharmacotherapy 26 (2006): 269-76
Go AC, Golightly LK, Barber GR, Barron MA "Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment." Drug Metabol Drug Interact 25(1-4) (2010): 41-7
Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790
Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61
Lorenz RA, Vandenberg AM, Canepa EA "Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases." Int J Psychiatry Med 38 (2008): 81-90
Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5
Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8
Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5
Morrison EK, Rowe AS "Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia." J Clin Pharm Ther 37 (2012): 610-3
FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Ayvox) is given to patients taking certain psychiatric medications. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm#table." ([2011 July 26]):
Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3
Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9
Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9
Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8